[{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"eIF4E","graph1":"Oncology","graph2":"Discovery","graph3":"Effector Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Effector Therapeutics \/ Pfizer"},{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Allogeneic T-cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Immatics \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Stony Brook University","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","graph1":"Oncology","graph2":"Discovery","graph3":"Stony Brook University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Stony Brook University \/ National Cancer Institute","highestDevelopmentStatusID":"2","companyTruncated":"Stony Brook University \/ National Cancer Institute"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CT-1","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Riptide Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Riptide Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Riptide Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCR based Natural Killer cell","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Institutet \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"2","companyTruncated":"Karolinska Institutet \/ Zelluna Immunotherapy"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas ","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"T-cell bispecific antibodies","moa":"CD3","graph1":"Oncology","graph2":"Discovery","graph3":"CytomX Therapeutics","amount2":1.6000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.6000000000000001,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Astellas ","highestDevelopmentStatusID":"2","companyTruncated":"CytomX Therapeutics \/ Astellas "},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Debio 0228","moa":"CA IX","graph1":"Oncology","graph2":"Discovery","graph3":"3B Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ Debiopharm","highestDevelopmentStatusID":"2","companyTruncated":"3B Pharmaceuticals \/ Debiopharm"},{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Not Applicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"TCR-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"TScan Therapeutics \/ Novartis"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugates","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RNA targeted small molecule","moa":"RNA","graph1":"Oncology","graph2":"Discovery","graph3":"Arrakis Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Arrakis Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Arrakis Therapeutics \/ Roche"},{"orgOrder":0,"company":"oNKo-innate","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"NK cell therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"oNKo-innate","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"oNKo-innate \/ Gilead","highestDevelopmentStatusID":"2","companyTruncated":"oNKo-innate \/ Gilead"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Rome Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Vocimagene amiretrorepvec","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Biosciences \/ Denovo Biopharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"CTGF","graph1":"Oncology","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biologics \/ Aravive"},{"orgOrder":0,"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ University of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ University of Montreal"},{"orgOrder":0,"company":"Alivexis","sponsor":"SBI Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"Alivexis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Alivexis \/ SBI Investments","highestDevelopmentStatusID":"2","companyTruncated":"Alivexis \/ SBI Investments"},{"orgOrder":0,"company":"Abveris","sponsor":"Nkarta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Abveris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Abveris \/ Nkarta","highestDevelopmentStatusID":"2","companyTruncated":"Abveris \/ Nkarta"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tak-733","moa":"MEK1\/2","graph1":"Oncology","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Recursion","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pharmaceutical \/ Recursion"},{"orgOrder":0,"company":"SeraNovo","sponsor":"Carna Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"SeraNovo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SeraNovo \/ Carna Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"SeraNovo \/ Carna Bioscience"},{"orgOrder":0,"company":"Alvaxa Biosciences","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Nanobodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alvaxa Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alvaxa Biosciences \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Alvaxa Biosciences \/ Sensei Biotherapeutics"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Tumor-infiltrating Treg","moa":"IL-2","graph1":"Oncology","graph2":"Discovery","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Egle Therapeutics \/ Takeda"},{"orgOrder":0,"company":"Vernalis","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Lysosome targeting chimeras","moa":"Apolipoprotein-E4","graph1":"Oncology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Almac Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ADP-c165","moa":"RTK transmembrane receptor ROR1","graph1":"Oncology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Almac Group \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Gene and Cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sana Biotechnology","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Sana Biotechnology \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Multi-specific antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Numab Therapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Quantitative Medicine","sponsor":"Predictive Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Quantitative Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Quantitative Medicine \/ Predictive Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Quantitative Medicine \/ Predictive Oncology"},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"T Cell Engaging Bispecific Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ Xencor"},{"orgOrder":0,"company":"Var2 Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"rVAR2 Drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Var2 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Var2 Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Var2 Pharmaceuticals \/ Merck"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Takeda"},{"orgOrder":0,"company":"Aichi Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Neoantigen","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aichi Cancer Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aichi Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Aichi Cancer Center \/ Not Applicable"},{"orgOrder":0,"company":"Revitope Oncology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Immunotherapy compound","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Revitope Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Revitope Oncology \/ Junshi Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Revitope Oncology \/ Junshi Biosciences"},{"orgOrder":0,"company":"Kobe University","sponsor":"Lynk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kobe University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kobe University \/ Lynk Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kobe University \/ Lynk Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ MD Anderson"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Viva Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Viva Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Viva Biotech"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Seismic Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Bispecific antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Seismic Bio","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Seismic Bio"},{"orgOrder":0,"company":"Matterhorn Biosciences","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"T cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Matterhorn Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Matterhorn Biosciences \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Matterhorn Biosciences \/ Versant Ventures"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"p53 protein","graph1":"Oncology","graph2":"Discovery","graph3":"PMV Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"PMV Pharma \/ Avoro Capital","highestDevelopmentStatusID":"2","companyTruncated":"PMV Pharma \/ Avoro Capital"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Vir Biotechnology"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-AML specific antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Therapeutics \/ Kite"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Redx Pharma","amount2":0.41999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Redx Pharma \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"C0021158","moa":"Arginase 2","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"mRNA therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Nutcracker Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Bi-specific antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Immetas Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"Tmod-engineered T cells","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"A2 Biotherapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ The Column Group","highestDevelopmentStatusID":"2","companyTruncated":"A2 Biotherapeutics \/ The Column Group"},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Abveris","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Berkeley Lights","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Berkeley Lights \/ Abveris","highestDevelopmentStatusID":"2","companyTruncated":"Berkeley Lights \/ Abveris"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Neogene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"CAR-T cell therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Neogene","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Neogene"},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Arvinas \/ Not Applicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Broad Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"PARG","graph1":"Oncology","graph2":"Discovery","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Broad Institute","highestDevelopmentStatusID":"2","companyTruncated":"Ideaya Biosciences \/ Broad Institute"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Radioactive labelled-antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"PhoreMost","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"LentiVector based gene therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ Oxford Biomedica","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost \/ Oxford Biomedica"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":0.80000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Seed Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-2 alpha","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":2.7599999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Schrodinger \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"2","companyTruncated":"Y-Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"Domainex","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"APN431","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Domainex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Domainex \/ APEIRON Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/ APEIRON Biologics"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Egle Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":2.5600000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.5600000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"iBio","sponsor":"ATB Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Atbody-st-2","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ ATB Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"iBio \/ ATB Therapeutics"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Humabody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Crescendo Biologics Ltd \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Crescendo Biologics Ltd \/ Takeda"},{"orgOrder":0,"company":"InveniAI","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InveniAI \/ Kyowa Kirin","highestDevelopmentStatusID":"2","companyTruncated":"InveniAI \/ Kyowa Kirin"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Tumor Activated T Cell Engager","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Janux Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Janux Therapeutics \/ Merck"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ Servier"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Exo Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Exo Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"2","companyTruncated":"Exo Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Teijin Pharma \/ TransThera Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Teijin Pharma \/ TransThera Biosciences"},{"orgOrder":0,"company":"Princeton University","sponsor":"Barer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SHMT","graph1":"Oncology","graph2":"Discovery","graph3":"Princeton University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Princeton University \/ Barer Institute","highestDevelopmentStatusID":"2","companyTruncated":"Princeton University \/ Barer Institute"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Cell therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"Oxford Biotherapeutics \/ Kite"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Next-generation T cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"SHP2","graph1":"Oncology","graph2":"Discovery","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Taiho Pharmaceutical \/ Merck"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Logos Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Kepa1-Nrf2","graph1":"Oncology","graph2":"Discovery","graph3":"Vividion Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Vividion Therapeutics \/ Logos Capital","highestDevelopmentStatusID":"2","companyTruncated":"Vividion Therapeutics \/ Logos Capital"},{"orgOrder":0,"company":"Cellarity","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cellarity","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Cellarity \/ BlackRock","highestDevelopmentStatusID":"2","companyTruncated":"Cellarity \/ BlackRock"},{"orgOrder":0,"company":"Merus","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific antibody therapies","moa":"CD3","graph1":"Oncology","graph2":"Discovery","graph3":"Merus","amount2":1.6599999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.6599999999999999,"dosageForm":"","sponsorNew":"Merus \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Merus \/ Eli Lilly"},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"LSD1 allosteric","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pathios Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Pathios Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"2","companyTruncated":"Pathios Therapeutics \/ Innovate UK"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Alpha Radio Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aktis Oncology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Aktis Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"2","companyTruncated":"Aktis Oncology \/ EcoR1 Capital"},{"orgOrder":0,"company":"NanoSmart Pharmaceuticals","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Dactinomycin","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"NanoSmart Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NanoSmart Pharmaceuticals \/ Oncology Pharma","highestDevelopmentStatusID":"2","companyTruncated":"NanoSmart Pharmaceuticals \/ Oncology Pharma"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"ONKT101","moa":"CCR7 receptor","graph1":"Oncology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ ONK Therapeutics"},{"orgOrder":0,"company":"Harvard University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Harvard University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Harvard University \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"Harvard University \/ Astellas"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"ecDNA-directed therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Boundless Bio","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Boundless Bio \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Boundless Bio \/ Nextech Invest"},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Syngene International Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Syngene International Limited \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Syngene International Limited \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Transcription factor","graph1":"Oncology","graph2":"Discovery","graph3":"Flare Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Flare Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"BioMed X","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioMed X","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioMed X \/ Merck KGA","highestDevelopmentStatusID":"2","companyTruncated":"BioMed X \/ Merck KGA"},{"orgOrder":0,"company":"Appia Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"CAR-iNKT","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Appia Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Appia Bio \/ 8VC","highestDevelopmentStatusID":"2","companyTruncated":"Appia Bio \/ 8VC"},{"orgOrder":0,"company":"Aptamer Group","sponsor":"PinotBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"FL-118-based Drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aptamer Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aptamer Group \/ PinotBio","highestDevelopmentStatusID":"2","companyTruncated":"Aptamer Group \/ PinotBio"},{"orgOrder":0,"company":"Trinity College Dublin","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ONKT103","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Trinity College Dublin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Trinity College Dublin \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Trinity College Dublin \/ ONK Therapeutics"},{"orgOrder":0,"company":"University of Florida","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"OM301","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"University of Florida \/ OncoMyx","highestDevelopmentStatusID":"2","companyTruncated":"University of Florida \/ OncoMyx"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Allogeneic Cell Therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shoreline Biosciences","amount2":2.2999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.2999999999999998,"dosageForm":"","sponsorNew":"Shoreline Biosciences \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"Shoreline Biosciences \/ Kite"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group and Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cyclin A","graph1":"Oncology","graph2":"Discovery","graph3":"Circle Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ The Column Group and Nextech","highestDevelopmentStatusID":"2","companyTruncated":"Circle Pharma \/ The Column Group and Nextech"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kumquat Biosciences","amount2":2.0699999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0699999999999998,"dosageForm":"","sponsorNew":"Kumquat Biosciences \/ Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Kumquat Biosciences \/ Lilly"},{"orgOrder":0,"company":"Macomics","sponsor":"Caribou Property Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Macrophage-based Therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Macomics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Macomics \/ Caribou Property Limited","highestDevelopmentStatusID":"2","companyTruncated":"Macomics \/ Caribou Property Limited"},{"orgOrder":0,"company":"Q-State Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"Antisense Oligonucleotide Therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Q-State Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Q-State Biosciences \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"Q-State Biosciences \/ NIH"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MOLCURE Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ MOLCURE Inc","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ MOLCURE Inc"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DNA","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0.34000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Schrodinger \/ Zai Lab","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Zai Lab"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0.70999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Incyte","highestDevelopmentStatusID":"2","companyTruncated":"Nimble Therapeutics \/ Incyte"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ Sanofi Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Rome Therapeutics \/ Sanofi Ventures"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Allogeneic T-cell Therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adaptimmune Therapeutics","amount2":3.2999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":3.2999999999999998,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Adaptimmune Therapeutics \/ Roche"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"858 Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"858 Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"858 Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Single-domain Antibody","moa":"Checkpoint","graph1":"Oncology","graph2":"Discovery","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ AskGene","highestDevelopmentStatusID":"2","companyTruncated":"GenScript ProBio \/ AskGene"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Exo Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Exo Therapeutics \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Exo Therapeutics \/ Nextech Invest"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tetravalent Bispecific Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"F-star Therapeutics","amount2":1.3700000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.3700000000000001,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Janssen","highestDevelopmentStatusID":"2","companyTruncated":"F-star Therapeutics \/ Janssen"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Ab Magnitude Ventures Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Ab Magnitude Ventures Group","highestDevelopmentStatusID":"2","companyTruncated":"SpringWorks Therapeutics \/ Ab Magnitude Ventures Group"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Albert Einstein College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Albert Einstein College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Orange Grove Bio \/ Albert Einstein College of Medicine"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BridgeBio Pharma \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio Pharma \/ Columbia University"},{"orgOrder":0,"company":"Dunad Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"Dunad Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.3200000000000001,"dosageForm":"Oral","sponsorNew":"Dunad Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Dunad Therapeutics \/ Novartis"},{"orgOrder":0,"company":"Clade Therapeutics","sponsor":"Syncona Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Induced Pluripotent Stem Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Clade Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Clade Therapeutics \/ Syncona Ltd.","highestDevelopmentStatusID":"2","companyTruncated":"Clade Therapeutics \/ Syncona Ltd."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Integral Molecular","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Monoclonal Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"AstraZeneca \/ Integral Molecular","highestDevelopmentStatusID":"2","companyTruncated":"AstraZeneca \/ Integral Molecular"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"GDA-501","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Gamida Cell \/ Not Applicable"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"LCB20A","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Dosage Strength\/Form","sponsorNew":"LegoChem Biosciences \/ SOTIO","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ SOTIO"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Pierre Fabre \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Pierre Fabre \/ Talem Therapeutics"},{"orgOrder":0,"company":"Novadiscovery","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Novadiscovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Novadiscovery \/ Janssen","highestDevelopmentStatusID":"2","companyTruncated":"Novadiscovery \/ Janssen"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Talem Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"2","companyTruncated":"Talem Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"DARPin-conjugated Radioligand Therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Molecular Partners","amount2":0.57999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"Intratumoral","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Molecular Partners \/ Novartis"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HPK1","graph1":"Oncology","graph2":"Discovery","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Cullinan Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"In-vivo Engineered CAR Monocyte Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Carisma Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"Carisma Therapeutics \/ Moderna"},{"orgOrder":0,"company":"SEngine Precision Medicine","sponsor":"Oncodesign","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"SEngine Precision Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SEngine Precision Medicine \/ Oncodesign","highestDevelopmentStatusID":"2","companyTruncated":"SEngine Precision Medicine \/ Oncodesign"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0.25,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"","sponsorNew":"Twist Bioscience \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"AvantGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adcentrx Therapeutics \/ AvantGen","highestDevelopmentStatusID":"2","companyTruncated":"Adcentrx Therapeutics \/ AvantGen"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Actinium-225 Conjugated Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ AVEO Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Actinium pharmaceuticals \/ AVEO Oncology"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Twist Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Therapeutics \/ Twist Bioscience"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ University of Minnesota","highestDevelopmentStatusID":"2","companyTruncated":"Catamaran Bio \/ University of Minnesota"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"WEE1","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Not Applicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"KayoThera","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"KayoThera","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"KayoThera \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"2","companyTruncated":"KayoThera \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"RNAGENE Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ RNAGENE Inc.","highestDevelopmentStatusID":"2","companyTruncated":"PharmAbcine \/ RNAGENE Inc."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"NuclixBio Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ NuclixBio Inc.","highestDevelopmentStatusID":"2","companyTruncated":"PharmAbcine \/ NuclixBio Inc."},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"NVIDIA Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regor Therapeutics \/ NVIDIA Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Regor Therapeutics \/ NVIDIA Corporation"},{"orgOrder":0,"company":"HitGen","sponsor":"Uppthera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Uppthera","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Uppthera"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MediSix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ MediSix","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ MediSix"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"GGV Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ensem Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Ensem Therapeutics \/ GGV Capital","highestDevelopmentStatusID":"2","companyTruncated":"Ensem Therapeutics \/ GGV Capital"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MDNA413","moa":"IL-4\/IL-13 ant","graph1":"Oncology","graph2":"Discovery","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Medicenna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Harpoon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Poxvirus-based Antibody","moa":"SEMA4D","graph1":"Oncology","graph2":"Discovery","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Vaccinex \/ Not Applicable"},{"orgOrder":0,"company":"Engimmune Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"T-cell Receptor Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Engimmune Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Extended-release Capsule","sponsorNew":"Engimmune Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"2","companyTruncated":"Engimmune Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Garvan Institute of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Microba Life Sciences \/ Garvan Institute of Medical Research","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Garvan Institute of Medical Research"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Comera Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Comera Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Astellas"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"MR1","graph1":"Oncology","graph2":"Discovery","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enara Bio \/ Monash University","highestDevelopmentStatusID":"2","companyTruncated":"Enara Bio \/ Monash University"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Black Diamond Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ CuraTeQ Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Orion Corporation \/ CuraTeQ Biologics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"XB010","moa":"5T4 oncofetal antigen","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VET-ROG1","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"KaliVir Immunotherapeutics \/ Roche"},{"orgOrder":0,"company":"Excelra","sponsor":"HotSpot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Excelra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Excelra \/ HotSpot Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ HotSpot Therapeutics"},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"HK inno.N","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Exosome-loaded Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ILIAS Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ILIAS Biologics \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"ILIAS Biologics \/ HK inno.N"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RAS-F","moa":"Pan-RAS","graph1":"Oncology","graph2":"Discovery","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Gamma-delta T Cell Adoptive Cell Therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Immatics","highestDevelopmentStatusID":"2","companyTruncated":"Editas Medicine \/ Immatics"},{"orgOrder":0,"company":"Aurigene","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0.44,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"","sponsorNew":"Aurigene \/ Olema","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/ Olema"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Immunostimulatory Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sutro Biopharma","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sutro Biopharma \/ Astellas Pharma"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Acc-225","moa":"Ionising radiation","graph1":"Oncology","graph2":"Discovery","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BWX Technologies \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"BWX Technologies \/ Bayer"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Harvard Medical School","highestDevelopmentStatusID":"2","companyTruncated":"BriaCell Therapeutics \/ Harvard Medical School"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-Drug Conjugate Based Therapeutic","moa":"STING","graph1":"Oncology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Innorna","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Innorna","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Innorna \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Innorna \/ BeiGene"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody Drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Glycotope GmbH","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Glycotope GmbH"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Auron Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"F-star Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"F-star Therapeutics \/ Takeda"},{"orgOrder":0,"company":"Biocytogen","sponsor":"LiberoThera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BCG005","moa":"CCR 8","graph1":"Oncology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ LiberoThera","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ LiberoThera"},{"orgOrder":0,"company":"University of Helsinki","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"EUROPE","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"PeptiCRAd","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"University of Helsinki","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"University of Helsinki \/ Valo Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"University of Helsinki \/ Valo Therapeutics"},{"orgOrder":0,"company":"SEngine Precision Medicine","sponsor":"Washington Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"SEngine Precision Medicine","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"SEngine Precision Medicine \/ Washington Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SEngine Precision Medicine \/ Washington Research Foundation"},{"orgOrder":0,"company":"BioCina","sponsor":"Australian Government Department of Industry","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"RNA-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioCina","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"BioCina \/ Australian Government Department of Industry","highestDevelopmentStatusID":"2","companyTruncated":"BioCina \/ Australian Government Department of Industry"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"iPSC-derived Allogeneic Immune Therapies","moa":"CD19","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio \/ Not Applicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Peptide-radioisotope Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ RayzeBio","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ RayzeBio"},{"orgOrder":0,"company":"Gicell","sponsor":"HK inno.N","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Gicell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gicell \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"Gicell \/ HK inno.N"},{"orgOrder":0,"company":"GNS healthcare","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GNS healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GNS healthcare \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"GNS healthcare \/ Servier"},{"orgOrder":0,"company":"Beactica","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Dong-A ST","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Dong-A ST"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bispecific Antibody Therapeutic","moa":"CHI3L1","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Voronoi","sponsor":"METiS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Pan-RAF","graph1":"Oncology","graph2":"Discovery","graph3":"Voronoi","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Voronoi \/ METiS Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Voronoi \/ METiS Therapeutics"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Guangzhou FineImmune Biotechnology Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"TCR-mimic Antibody-based Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Whitelab Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Debiopharm","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Debiopharm \/ Whitelab Genomics","highestDevelopmentStatusID":"2","companyTruncated":"Debiopharm \/ Whitelab Genomics"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Cartexell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Cell Therapy","moa":"CLND18.2","graph1":"Oncology","graph2":"Discovery","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Cartexell","highestDevelopmentStatusID":"2","companyTruncated":"Integral Molecular \/ Cartexell"},{"orgOrder":0,"company":"Bugworks","sponsor":"Cytecare Cancer Hospitals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bugworks \/ Cytecare Cancer Hospitals","highestDevelopmentStatusID":"2","companyTruncated":"Bugworks \/ Cytecare Cancer Hospitals"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign \/ Servier"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"T-cell Based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio \/ Genentech"},{"orgOrder":0,"company":"PhoreMost","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost \/ Roche"},{"orgOrder":0,"company":"Cellarity","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cellarity","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Cellarity \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Cellarity \/ Flagship Pioneering"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"V-Bio Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ V-Bio Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Biotech \/ V-Bio Ventures"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire Immune Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Therapeutics \/ General Catalyst"},{"orgOrder":0,"company":"PIC Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PIC Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"PIC Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"2","companyTruncated":"PIC Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"EN-2642","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Enosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Enosi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Enosi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"iPSC-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alterome Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alterome Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Alterome Therapeutics \/ Colt Ventures"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Tri-specific Antibody","moa":"CD40","graph1":"Oncology","graph2":"Discovery","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ ISU ABXIS Co.","highestDevelopmentStatusID":"2","companyTruncated":"Eucure Biopharma \/ ISU ABXIS Co."},{"orgOrder":0,"company":"Spanios","sponsor":"Unravel Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Spanios","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Spanios \/ Unravel Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Spanios \/ Unravel Biosciences"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ The Institute of Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"Rezo Therapeutics","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rezo Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Rezo Therapeutics \/ SR One","highestDevelopmentStatusID":"2","companyTruncated":"Rezo Therapeutics \/ SR One"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Opna Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Opna Bio \/ Longitude Capital","highestDevelopmentStatusID":"2","companyTruncated":"Opna Bio \/ Longitude Capital"},{"orgOrder":0,"company":"Ablexis","sponsor":"AlivaMab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Antibody-based Therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ablexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ablexis \/ AlivaMab","highestDevelopmentStatusID":"2","companyTruncated":"Ablexis \/ AlivaMab"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"TCR Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ AstraZeneca"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Aurigene","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aurigene \/ EQRx","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/ EQRx"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"ICR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ ICR","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ ICR"},{"orgOrder":0,"company":"Touchlight","sponsor":"Odimma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Odimma Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight \/ Odimma Therapeutics"},{"orgOrder":0,"company":"Biosion","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugates","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biosion \/ ImmunoGen","highestDevelopmentStatusID":"2","companyTruncated":"Biosion \/ ImmunoGen"},{"orgOrder":0,"company":"Alpha-9 Theranostics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Radiopharmaceutical","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha-9 Theranostics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Alpha-9 Theranostics \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Alpha-9 Theranostics \/ Nextech Invest"},{"orgOrder":0,"company":"Etcembly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Etcembly","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Etcembly \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Etcembly \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Innate Pharma","amount2":1.47,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"XtalPi","sponsor":"EDDC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ EDDC","highestDevelopmentStatusID":"2","companyTruncated":"XtalPi \/ EDDC"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Mersana Therapeutics","amount2":0.82999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.82999999999999996,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Mersana Therapeutics \/ Merck"},{"orgOrder":0,"company":"Ordaos Bio","sponsor":"Yatiri Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ordaos Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ordaos Bio \/ Yatiri Bio","highestDevelopmentStatusID":"2","companyTruncated":"Ordaos Bio \/ Yatiri Bio"},{"orgOrder":0,"company":"Oncorus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oncorus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Oncorus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Caris Life Sciences","amount2":0.19,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Xencor","highestDevelopmentStatusID":"2","companyTruncated":"Caris Life Sciences \/ Xencor"},{"orgOrder":0,"company":"Esperovax","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Circular RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Esperovax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Esperovax \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Esperovax \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"METiS Therapeutics","sponsor":"Evopoint Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"METiS Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"METiS Therapeutics \/ Evopoint Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"METiS Therapeutics \/ Evopoint Biosciences"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ EpiVax","highestDevelopmentStatusID":"2","companyTruncated":"GreenLight Biosciences \/ EpiVax"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kronos Bio","amount2":0.56999999999999995,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"","sponsorNew":"Kronos Bio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Kronos Bio \/ Genentech"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"T-cell based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"3T Biosciences","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"3T Biosciences \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Anima Biotech","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Anima Biotech","amount2":0.57999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Anima Biotech \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Anima Biotech \/ AbbVie"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Company \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ajinomoto Company \/ Exelixis"},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aethon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Aethon Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Aethon Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Exothera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"VALO-D102","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Exothera","highestDevelopmentStatusID":"2","companyTruncated":"Valo Therapeutics \/ Exothera"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"TCR-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ AstraZeneca"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Hinge Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hinge Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Hinge Bio \/ Not Applicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Innate Pharma","amount2":1.5,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Evotec","amount2":0.34999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"COTA","sponsor":"Clinical Research Data Sharing Alliance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"COTA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"COTA \/ Clinical Research Data Sharing Alliance","highestDevelopmentStatusID":"2","companyTruncated":"COTA \/ Clinical Research Data Sharing Alliance"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CNTY-104","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Century Therapeutics","amount2":3.1499999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":3.1499999999999999,"dosageForm":"","sponsorNew":"Century Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Century Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Crescendo Biologics Ltd","amount2":0.79000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.79000000000000004,"dosageForm":"","sponsorNew":"Crescendo Biologics Ltd \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Crescendo Biologics Ltd \/ BioNTech"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Mersana Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.04,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Mersana Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Immunogen","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Camptothecin-based Antibody Conjugate","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Discovery","graph3":"Immunogen","amount2":1.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.75,"dosageForm":"","sponsorNew":"Immunogen \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Immunogen \/ Eli Lilly"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adagene Suzhou Limited","amount2":2.52,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.52,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Adagene Suzhou Limited \/ Sanofi"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"Amphista Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Inhalation","sponsorNew":"Amphista Therapeutics \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"Amphista Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"GO Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GO Therapeutics","amount2":0.78000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"GO Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GO Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":2.0499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":1.25,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.25,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":2.0499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Federation Bio","sponsor":"MD Anderson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Microbiome-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Federation Bio \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Federation Bio \/ MD Anderson"},{"orgOrder":0,"company":"Synaffix","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":0.13,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Synaffix \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ReviR Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"ReviR Therapeutics \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mythic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mythic Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mythic Therapeutics"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dren Bio","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"","sponsorNew":"Dren Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Dren Bio \/ Pfizer Inc"},{"orgOrder":0,"company":"Elthera","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Elthera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elthera \/ LegoChem Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Elthera \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Universit\u00e9 de Montr\u00e9al \/ Ipsen"},{"orgOrder":0,"company":"Xilis","sponsor":"MD Anderson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Xilis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xilis \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Xilis \/ MD Anderson"},{"orgOrder":0,"company":"M2Gen","sponsor":"Zephyr AI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"M2Gen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"M2Gen \/ Zephyr AI","highestDevelopmentStatusID":"2","companyTruncated":"M2Gen \/ Zephyr AI"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived VHH Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bispecific Antibody Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"BRAIN Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ BRAIN Biotech","highestDevelopmentStatusID":"2","companyTruncated":"TransCode Therapeutics \/ BRAIN Biotech"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Phanes Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Alpha Fusion","sponsor":"Sumitomo Heavy Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Astatine-211","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha Fusion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpha Fusion \/ Sumitomo Heavy Industries","highestDevelopmentStatusID":"2","companyTruncated":"Alpha Fusion \/ Sumitomo Heavy Industries"},{"orgOrder":0,"company":"Simris Group","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-Drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Simris Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Simris Group \/ Lonza Group","highestDevelopmentStatusID":"2","companyTruncated":"Simris Group \/ Lonza Group"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Libera Bio","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Libera Bio","amount2":0.16,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Libera Bio \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Libera Bio \/ Talem Therapeutics"},{"orgOrder":0,"company":"Protai","sponsor":"Grove Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Protai","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Protai \/ Grove Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Protai \/ Grove Ventures"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"F-star Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"NeoGenomics","sponsor":"Massive Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"NeoGenomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NeoGenomics \/ Massive Bio","highestDevelopmentStatusID":"2","companyTruncated":"NeoGenomics \/ Massive Bio"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Yonsei University Health System","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Yonsei University Health System","highestDevelopmentStatusID":"2","companyTruncated":"Orange Grove Bio \/ Yonsei University Health System"},{"orgOrder":0,"company":"Macomics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Macomics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":1.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.75,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Novartis"},{"orgOrder":0,"company":"Covant Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Covant Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Covant Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Covant Therapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"T\u03c5HURA Biopharma","sponsor":"Morphogenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"T\u03c5HURA Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"T\u03c5HURA Biopharma \/ Morphogenesis","highestDevelopmentStatusID":"2","companyTruncated":"T\u03c5HURA Biopharma \/ Morphogenesis"},{"orgOrder":0,"company":"Simulations Plus","sponsor":"SACF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Simulations Plus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Simulations Plus \/ SACF","highestDevelopmentStatusID":"2","companyTruncated":"Simulations Plus \/ SACF"},{"orgOrder":0,"company":"Galapagos","sponsor":"NovAliX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Galapagos \/ NovAliX","highestDevelopmentStatusID":"2","companyTruncated":"Galapagos \/ NovAliX"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Predictive Oncology \/ Integra Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Predictive Oncology \/ Integra Therapeutics"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Talem Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Talem Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Evergreen Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Evergreen Discovery"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioTheryX","amount2":0.35999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"BioTheryX \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"BioTheryX \/ Incyte Corporation"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Queen\u2019s University Belfast","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aviceda Therapeutics \/ Queen\u2019s University Belfast","highestDevelopmentStatusID":"2","companyTruncated":"Aviceda Therapeutics \/ Queen\u2019s University Belfast"},{"orgOrder":0,"company":"Genmab","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Argenx","highestDevelopmentStatusID":"2","companyTruncated":"Genmab \/ Argenx"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"OpenBench","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"OpenBench","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OpenBench \/ Tavros Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"OpenBench \/ Tavros Therapeutics"},{"orgOrder":0,"company":"Plasticell","sponsor":"LambdaGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"iPSC-derived Allogenic Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Plasticell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Plasticell \/ LambdaGen","highestDevelopmentStatusID":"2","companyTruncated":"Plasticell \/ LambdaGen"},{"orgOrder":0,"company":"Ten63 Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ten63 Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Ten63 Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ten63 Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Medigene"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"German Cancer Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Bicyclic Peptide-based Radio Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ German Cancer Research Center","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ German Cancer Research Center"},{"orgOrder":0,"company":"Cullgen","sponsor":"AZ-CICC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cullgen \/ AZ-CICC","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ AZ-CICC"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Bicyclic Peptide-based Radio Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":1.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.75,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Ariceum Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"McMaster University","sponsor":"Brain Cancer Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"CAR-T Cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"McMaster University \/ Brain Cancer Canada","highestDevelopmentStatusID":"2","companyTruncated":"McMaster University \/ Brain Cancer Canada"},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"NVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CHARM Therapeutics \/ NVentures","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Therapeutics \/ NVentures"},{"orgOrder":0,"company":"Sony Corporation","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sony Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sony Corporation \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sony Corporation \/ Astellas Pharma"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Servier","sponsor":"Aitia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Servier \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ Aitia"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Duke University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunoforge \/ Duke University","highestDevelopmentStatusID":"2","companyTruncated":"Immunoforge \/ Duke University"},{"orgOrder":0,"company":"PharmEnable","sponsor":"MP Healthcare Venture Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmEnable","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"PharmEnable \/ MP Healthcare Venture Management","highestDevelopmentStatusID":"2","companyTruncated":"PharmEnable \/ MP Healthcare Venture Management"},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Polaris Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Larkspur Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Larkspur Biosciences \/ Polaris Innovation Fund","highestDevelopmentStatusID":"2","companyTruncated":"Larkspur Biosciences \/ Polaris Innovation Fund"},{"orgOrder":0,"company":"Anocca","sponsor":"AMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"TCR-T-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Anocca","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Anocca \/ AMF","highestDevelopmentStatusID":"2","companyTruncated":"Anocca \/ AMF"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ University Health Network","highestDevelopmentStatusID":"2","companyTruncated":"Providence Therapeutics \/ University Health Network"},{"orgOrder":0,"company":"MEDIC Life Sciences","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"MEDIC Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MEDIC Life Sciences \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"MEDIC Life Sciences \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Bielefeld University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Cryptophycin Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Bielefeld University","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Pharma \/ Bielefeld University"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham"},{"orgOrder":0,"company":"CancerVAX","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CancerVAX \/ UCLA","highestDevelopmentStatusID":"2","companyTruncated":"CancerVAX \/ UCLA"},{"orgOrder":0,"company":"CancerVAX","sponsor":"StartEngine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Cancer Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"CancerVAX","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"CancerVAX \/ StartEngine","highestDevelopmentStatusID":"2","companyTruncated":"CancerVAX \/ StartEngine"},{"orgOrder":0,"company":"Cullgen","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Cullgen \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Astellas Pharma"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"UPMC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Radiopharmaceutical","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaLogic \/ UPMC","highestDevelopmentStatusID":"2","companyTruncated":"PharmaLogic \/ UPMC"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Biological Product","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Aimed Bio"},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Applied Biomedical Science Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biomedical Science Institute \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Crossbow Therapeutics","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"TCR-mimetic Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Crossbow Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Crossbow Therapeutics \/ MPM BioImpact","highestDevelopmentStatusID":"2","companyTruncated":"Crossbow Therapeutics \/ MPM BioImpact"},{"orgOrder":0,"company":"leadXpro","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"leadXpro","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"leadXpro \/ Cumulus Oncology","highestDevelopmentStatusID":"2","companyTruncated":"leadXpro \/ Cumulus Oncology"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"InxMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ InxMed","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ InxMed"},{"orgOrder":0,"company":"KayoThera","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"KayoThera","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"KayoThera \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"2","companyTruncated":"KayoThera \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"ImmunoBiochem","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ImmunoBiochem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoBiochem \/ ImmunoGen","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoBiochem \/ ImmunoGen"},{"orgOrder":0,"company":"Peking University","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Peking University \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Peking University \/ Bayer AG"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Astex Pharmaceuticals","amount2":0.54000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Astex Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Syros Pharmaceuticals","amount2":0.19,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Syros Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Tentarix Biotherapeutics","amount2":0.31,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Tentarix Biotherapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"TFC Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"TFC Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TFC Therapeutics \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"TFC Therapeutics \/ Columbia University"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Verastem Oncology","amount2":0.64000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Celularity","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allogeneic Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Celularity \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"CCM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"KRAS Gene Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"CCM Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CCM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"CCM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"XtalPi","sponsor":"Incendia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ Parthenon Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"XtalPi \/ Parthenon Therapeutics"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Oranomed","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Oranomed"},{"orgOrder":0,"company":"Chemify","sponsor":"Dewpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Chemify","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Chemify \/ Dewpoint Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Chemify \/ Dewpoint Therapeutics"},{"orgOrder":0,"company":"Athebio","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"DARPin-targeted Radioligand","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Athebio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Athebio \/ POINT Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Athebio \/ POINT Biopharma"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"MDG2011","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Not Applicable"},{"orgOrder":0,"company":"Hyku Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Hyku Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Hyku Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Hyku Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BenevolentAI","amount2":0.58999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"BenevolentAI \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"BenevolentAI \/ Merck Group"},{"orgOrder":0,"company":"Adimab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Adimab \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Myeloid Immune Checkpoint Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ PharmaEssentia","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biologics \/ PharmaEssentia"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0.19,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"The Mark Foundation for Cancer Research","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"The Mark Foundation for Cancer Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Mark Foundation for Cancer Research \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"The Mark Foundation for Cancer Research \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ LegoChem Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Glycotope \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Monte Rosa Therapeutics","amount2":2.0499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Radionetics Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radionetics Oncology \/ GordonMD Global Investments","highestDevelopmentStatusID":"2","companyTruncated":"Radionetics Oncology \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Terremoto Biosciences","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Terremoto Biosciences \/ EcoR1 Capital","highestDevelopmentStatusID":"2","companyTruncated":"Terremoto Biosciences \/ EcoR1 Capital"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CAR T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Epic Bio \/ Kite Pharma"},{"orgOrder":0,"company":"Cellectis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cellectis","amount2":0.94999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cellectis \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Cellectis \/ AstraZeneca"},{"orgOrder":0,"company":"NuclixBio","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Circular RNA-based Drug","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"NuclixBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NuclixBio \/ GenScript ProBio","highestDevelopmentStatusID":"2","companyTruncated":"NuclixBio \/ GenScript ProBio"},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Phenomic AI","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Phenomic AI \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Phenomic AI \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"IBM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ IBM","highestDevelopmentStatusID":"2","companyTruncated":"Boehringer Ingelheim GmbH \/ IBM"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Chengwei Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Chengwei Capital","highestDevelopmentStatusID":"2","companyTruncated":"Shape Therapeutics \/ Chengwei Capital"},{"orgOrder":0,"company":"Peptone","sponsor":"The Institute of Oncology Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Peptone","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Peptone \/ The Institute of Oncology Research","highestDevelopmentStatusID":"2","companyTruncated":"Peptone \/ The Institute of Oncology Research"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Prelude Therapeutics \/ AbCellera"},{"orgOrder":0,"company":"IPGaia","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"IPGaia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IPGaia \/ Duke-NUS Medical School","highestDevelopmentStatusID":"2","companyTruncated":"IPGaia \/ Duke-NUS Medical School"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CAR T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"PostEra","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PostEra \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"PostEra \/ Amgen Inc"},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Glycotope \/ Evotec"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Degrader-antibody Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"C4 Therapeutics","amount2":0.60999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"C4 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Etherna","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Etherna","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Etherna \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"Etherna \/ Almirall"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nerviano Medical Sciences \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"2","companyTruncated":"Nerviano Medical Sciences \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ IASO BIO","highestDevelopmentStatusID":"2","companyTruncated":"Umoja Biopharma \/ IASO BIO"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Radionetics Oncology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Radionetics Oncology \/ Frazier Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Radionetics Oncology \/ Frazier Life Sciences"},{"orgOrder":0,"company":"BlossomHill Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BlossomHill Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"BlossomHill Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"BlossomHill Therapeutics \/ Colt Ventures"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Nanna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Nanna Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ubiquigent \/ Nanna Therapeutics"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Experimental Drug Development Centre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"TCR-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoScape \/ Experimental Drug Development Centre","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoScape \/ Experimental Drug Development Centre"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Curve Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Curve Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Curve Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NTX-470","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nutcracker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"APN-497444","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Atreca \/ Immunome","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ Immunome"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Astellas Pharma \/ Mass General Brigham"},{"orgOrder":0,"company":"Modulus Therapeutics","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Modulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Modulus Therapeutics \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Modulus Therapeutics \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"CancerVAX","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"CancerVAX \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"CancerVAX \/ Undisclosed"},{"orgOrder":0,"company":"Spanios","sponsor":"Rare Cancer Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Spanios","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Spanios \/ Rare Cancer Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Spanios \/ Rare Cancer Research Foundation"},{"orgOrder":0,"company":"CureVac","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"CureVac \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prism Biolab \/ ONO Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biolab \/ ONO Pharmaceutical"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alphamab Oncology","amount2":0.62,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ ArriVent","highestDevelopmentStatusID":"2","companyTruncated":"Alphamab Oncology \/ ArriVent"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CLD-400","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Calidi Biotherapeutics \/ SIGA Technologies"},{"orgOrder":0,"company":"Shinobi Therapeutics","sponsor":"Anocca AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"iPS-T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shinobi Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shinobi Therapeutics \/ Anocca AB","highestDevelopmentStatusID":"2","companyTruncated":"Shinobi Therapeutics \/ Anocca AB"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Adcytherix","sponsor":"Pontifax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"ADC-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adcytherix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Adcytherix \/ Pontifax","highestDevelopmentStatusID":"2","companyTruncated":"Adcytherix \/ Pontifax"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"T Cell Engager","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Marengo Therapeutics","amount2":1.2,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Marengo Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Rapafusyn Pharmaceuticals","sponsor":"3E Bioventures Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rapafusyn Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Rapafusyn Pharmaceuticals \/ 3E Bioventures Capital","highestDevelopmentStatusID":"2","companyTruncated":"Rapafusyn Pharmaceuticals \/ 3E Bioventures Capital"},{"orgOrder":0,"company":"Cypris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cypris Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cypris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Cypris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Biotech \/ University of Texas MD Anderson Cancer Center"}]
Find Novel Oncology Drugs in Discovery
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
